Melanoma Dispatch
2.6K views | +1 today
Follow
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Adjuvant Ipilimumab Improved RFS in High-Risk, Stage III Melanoma

Adjuvant Ipilimumab Improved RFS in High-Risk, Stage III Melanoma | Melanoma Dispatch | Scoop.it

"Adjuvant ipilimumab significantly improved RFS compared with placebo among patients with resected stage III melanoma who were at high risk for recurrence, according to the final analysis of a phase 3 study presented at the ASCO Annual Meeting.


“ 'Although there are approved adjuvant therapies, they are still to be improved, and this is clearly an unmet need,' researcher Alexander Eggermont, MD, PhD, director general of the Gustave Roussy Cancer Campus Grand Paris in France, said during a press conference. 'Ipilimumab is the first drug approved for metastatic melanoma, based on a proven impact on OS. This is the first trial ever with a drug that had an improvement in OS in metastatic melanoma.' "


Editor's note: Patients with advanced melanoma who have their tumors removed by surgery ("resected") can be at high risk for recurrence of their cancer. In a clinical trial with volunteer patients, researchers are testing an "adjuvant" treatment meant to prevent recurrence. All patients had resected stage III melanoma. It was found that patients who took the drug ipilimumab (Yervoy) after resection had a significantly greater amount of time pass before recurrence than patients who took a placebo. Further follow-up of the patients will reveal effects on overall survival.

Cancer Commons's insight:

Healio  |  Jun 10, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

New Therapies Harness Power of the Immune System Against Cancer

New Therapies Harness Power of the Immune System Against Cancer | Melanoma Dispatch | Scoop.it

"New research on innovative immunotherapies for advanced or high-risk melanoma and cervical cancer were presented today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). These treatments – used alone or in combination – fight cancer by activating and amplifying the body's immune response to the disease.


"The new studies find high activity with investigative drugs for advanced melanoma, and show for the first time that ipilimumab, a treatment already approved for advanced melanoma, can substantially decrease the risk of melanoma recurrence in certain patients with earlier-stage disease. In addition, another small trial reports that a one-time, personalized immunotherapy treatment induces complete and long-lasting remissions in a small number of women with advanced cervical cancer – a disease with little to no effective treatment options."


Editor's note: Immunotherapies are treatments that boost a patient's own immune system to fight cancer. Learn more.

Cancer Commons's insight:

Medical Xpress  |  Jun 2, 2014

more...
No comment yet.